Article (Scientific journals)
Balancing benefits and risks of glucocorticoids in rheumatic diseases and other inflammatory joint disorders: new insights from emerging data. An expert consensus paper from the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO)
Cooper, C.; Bardin, T.; Brandi, M.L. et al.
2016In Aging Clinical and Experimental Research, 28 (1), p. 1-16
Peer Reviewed verified by ORBi
 

Files


Full Text
Balancing benefits and risks of glucocorticoids in rheumatic diseases and other inflammatory joint disorders new insights from emerging data. An expert consensus paper ....pdf
Publisher postprint (818.26 kB)
Request a copy

All documents in ORBi are protected by a user license.

Send to



Details



Keywords :
Rheumatoid arthritis; Rheumatic diseas; Osteoporosis; Cohort studies; Glucocorticoids; Inflammation
Abstract :
[en] Purpose: This consensus review article considers the question of whether glucocorticoid (GC) therapy is still relevant in the treatment of rheumatic diseases, with a particular focus on rheumatoid arthritis (RA), and whether its side effects can be adequately managed. Recent basic and clinical research on the molecular, cellular and clinical effects of GCs have considerably advanced our knowledge in this field. An overview of the subject seems appropriate. Methods: This review is the result of a multidisciplinary expert working group, organised by European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis. The recent literature was surveyed and the salient evidence synthetized. Results: The pathophysiological basis of RA (and other inflammatory rheumatic diseases) now strongly implicates the adaptive immune system in addition to innate mechanisms. The molecular effect of GCs and differential GC sensitivity is better understood, although exploiting this knowledge is still in its infancy. The newer treatment strategies of early and aggressive control of RA have greatly improved clinical outcomes, but improvements are still possible. Newer targeted anti-inflammatory drugs have made an important impact, yet they too are associated with numerous side effects. Discussion: Short durations of moderate doses of GCs are generally well tolerated and have a positive benefit/risk ratio. Patients should be assessed for fracture risk and bone preserving agents and be prescribed calcium and vitamin D supplementation. Conclusions: Within a strategy of a disease modifying approach to inflammatory disease, combination therapy including a GC is effective approach.
Disciplines :
General & internal medicine
Author, co-author :
Cooper, C.
Bardin, T.
Brandi, M.L.
Cacoub, P.
Caminis, J.
Civitelli, R.
Cutolo, M.
Dere, W.
Devogelaer, J.P.
Diez-Perez, A.
Einhorn, T.A.
Ethgen, Olivier ;  Université de Liège > Département des sciences de la santé publique > Santé publique : aspects spécifiques
Kanis, J.A.
Kaufman, J.M.
Kvien, T.K.
Lems, W.F.
McCloskey, E.
Miossec, P.
Reiter, S.
Ringe, J.
Rizzoli, R.
Saag, K.
Reginster, Jean-Yves  ;  Université de Liège > Département des sciences de la santé publique > Santé publique, Epidémiologie et Economie de la santé
More authors (14 more) Less
Language :
English
Title :
Balancing benefits and risks of glucocorticoids in rheumatic diseases and other inflammatory joint disorders: new insights from emerging data. An expert consensus paper from the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO)
Publication date :
February 2016
Journal title :
Aging Clinical and Experimental Research
ISSN :
1594-0667
eISSN :
1720-8319
Publisher :
Springer, Italy
Volume :
28
Issue :
1
Pages :
1-16
Peer reviewed :
Peer Reviewed verified by ORBi
Available on ORBi :
since 14 June 2016

Statistics


Number of views
58 (8 by ULiège)
Number of downloads
3 (3 by ULiège)

Scopus citations®
 
21
Scopus citations®
without self-citations
17
OpenCitations
 
17

Bibliography


Similar publications



Contact ORBi